C. Moluçon-Chabrot

发表

Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis

B. Chauffert, P. Fumoleau, P. Fargeot, 2006, Anti-cancer drugs.

Severe Aplastic Anemia Associated With Eosinophilic Fasciitis

F. Jardin, J. Picquenot, A. Laquérriere, 2013, Medicine.

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.

E. Deconinck, P. Colombat, N. Milpied, 2009, Blood.

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

R. Houot, F. Jardin, K. Hoang-Xuan, 2022, Bone Marrow Transplantation.

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

R. Houot, F. Jardin, K. Hoang-Xuan, 2020, Neurology.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

K. Hoang-Xuan, O. Chinot, N. Martin-Duverneuil, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS)

K. Hoang-Xuan, O. Chinot, P. Morel, 2016 .

Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.

P. Fenaux, C. Chomienne, O. Tournilhac, 2006, Haematologica.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

R. Houot, F. Jardin, K. Hoang-Xuan, 2016, Neuro-oncology.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study

R. Houot, K. Hoang-Xuan, O. Chinot, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

K. Hoang-Xuan, O. Chinot, R. Gressin, 2019, Annals of Oncology.

Outcome and impact of post‐remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia

J. Bay, O. Tournilhac, M. Berger, 2018, American journal of hematology.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients.

G. Salles, J. Bay, V. Escuret, 2019, The Journal of infection.

Case of thyroid involvement by multiple myeloma.

C. Darcha, F. Cachin, A. Kelly, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

R. Houot, K. Hoang-Xuan, R. Gressin, 2019, European journal of cancer.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network

K. Hoang-Xuan, O. Chinot, R. Gressin, 2016 .

Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network

R. Houot, K. Hoang-Xuan, R. Gressin, 2016 .

SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era

K. Hoang-Xuan, K. Mokhtari, E. Tabouret, 2022, Leukemia & lymphoma.

K. Hoang-Xuan, O. Chinot, R. Gressin, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia

X. Thomas, F. Tinquaut, A. Bourmaud, 2017, Hematology.

[Major therapeutic advances and new perspectives in onco-hematology].

J. Bay, P. Verrelle, O. Tournilhac, 2013, Bulletin du cancer.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia

F. Tinquaut, A. Bourmaud, J. Cahn, 2017, Hematology.

Lymphoma Obinutuzumab plus Lenalidomide ( GALEN ) for the treatment of relapse / refractory aggressive lymphoma : a phase II LYSA study

R. Houot, P. Feugier, H. Tilly, 2018 .

[Major therapeutic advances and new perspectives in onco-hematology].

P. Verrelle, J. Bay, J. Biau, 2013, Bulletin du cancer.

IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.

R. Houot, K. Hoang-Xuan, R. Gressin, 2017 .

A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy

R. Houot, G. Salles, R. Bouabdallah, 2018, Blood.